Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer



      Cancer is a major public health problem as the leading cause of death. Palliative treatment aimed to alleviate pain and nausea in patients with advanced disease is a cornerstone of oncology. In 2007, the Israeli Ministry of Health began providing approvals for medical cannabis for the palliation of cancer symptoms. The aim of this study is to characterize the epidemiology of cancer patients receiving medical cannabis treatment and describe the safety and efficacy of this therapy.


      We analyzed the data routinely collected as part of the treatment program of 2970 cancer patients treated with medical cannabis between 2015 and 2017.


      The average age was 59.5 ± 16.3 years, 54.6% women and 26.7% of the patients reported previous experience with cannabis. The most frequent types of cancer were: breast (20.7%), lung (13.6%), pancreatic (8.1%) and colorectal (7.9%) with 51.2% being at stage 4. The main symptoms requiring therapy were: sleep problems (78.4%), pain (77.7%, median intensity 8/10), weakness (72.7%), nausea (64.6%) and lack of appetite (48.9%). After six months of follow up, 902 patients (24.9%) died and 682 (18.8%) stopped the treatment. Of the remaining, 1211 (60.6%) responded; 95.9% reported an improvement in their condition, 45 patients (3.7%) reported no change and four patients (0.3%) reported deterioration in their medical condition.


      Cannabis as a palliative treatment for cancer patients seems to be well tolerated, effective and safe option to help patients cope with the malignancy related symptoms.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J.
        • Shin H.R.
        • Bray F.
        • Forman D.
        • Mathers C.
        • Parkin D.M.
        Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
        Int J Cancer. 2010; 127: 2893-2917
        • Johnson J.R.
        • Burnell-Nugent M.
        • Lossignol D.
        • Ganae-Motan E.D.
        • Potts R.
        • Fallon M.T.
        Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain.
        J Pain Symptom Manage. 2010; 39: 167-179
        • Ahmedzai S.
        • Brooks D.
        • Group T-FCT
        Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life.
        J Pain Symptom Manage. 1997; 13: 254-261
        • Caraceni A.
        • Hanks G.
        • Kaasa S.
        • Bennett M.I.
        • Brunelli C.
        • Cherny N.
        • et al.
        Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.
        Lancet Oncol. 2012; 13: e58-e68
        • Berman J.S.
        • Symonds C.
        • Birch R.
        Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
        Pain. 2004; 112: 299-306
        • Bakowski M.T.
        Advances in anti-emetic therapy.
        Cancer Treat Rev. 1984; 11: 237-256
        • Schwartzberg L.S.
        Chemotherapy-induced nausea and vomiting: clinician and patient perspectives.
        J Support Oncol. 2007; 5: 5-12
      1. National Academies of Sciences E, and Medicine. The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations for Research. National Academies Press.

        • Reinarman C.
        • Nunberg H.
        • Lanthier F.
        • Heddleston T.
        Who are medical marijuana patients? Population characteristics from nine California assessment clinics.
        J Psychoactive Drugs. 2011; 43: 128-135
        • Ferraz M.B.
        • Quaresma M.
        • Aquino L.
        • Atra E.
        • Tugwell P.
        • Goldsmith C.
        Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis.
        J Rheumatol. 1990; 17: 1022-1024
        • Farrar J.T.
        • Young J.P.
        • LaMoreaux L.
        • Werth J.L.
        • Poole R.M.
        Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
        Pain. 2001; 94: 149-158
        • Group W
        Development of the World Health Organization WHOQOL-BREF quality of life assessment.
        Psychol Med. 1998; 28: 551-558
        • Light M.K.
        • Orens A.
        • Lewandowski B.
        • Pickton T.
        Market Size and Demand for Marijuana in Colorado.
        209. Colorado Department of Revenue, Denver2014: 202014 (https://www coloradogov/pacific/sites/default/files/Market% 20Size%20and%20Demand%20Study,%20July)
        • Ilgen M.A.
        • Bohnert K.
        • Kleinberg F.
        • Jannausch M.
        • Bohnert A.S.
        • Walton M.
        • et al.
        Characteristics of adults seeking medical marijuana certification.
        Drug Alcohol Depend. 2013; 132: 654-659
        • Johnson J.R.
        • Lossignol D.
        • Burnell-Nugent M.
        • Fallon M.T.
        An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
        J Pain Symptom Manage. 2013; 46: 207-218
        • Portenoy R.K.
        • Ganae-Motan E.D.
        • Allende S.
        • Yanagihara R.
        • Shaiova L.
        • Weinstein S.
        • et al.
        Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
        J Pain. 2012; 13: 438-449
        • Juneja R.
        Opioids and cancer recurrence.
        Curr Opin Support Palliat Care. 2014; 8: 91-101
        • Mesgarpour B.
        • Griebler U.
        • Glechner A.
        • Kien C.
        • Strobelberger M.
        • Van Noord M.
        • et al.
        Extended-release opioids in the management of cancer pain: a systematic review of efficacy and safety.
        Eur J Pain. 2014; 18: 605-616
        • Reddy A.
        • Yennurajalingam S.
        • Pulivarthi K.
        • Palla S.L.
        • Wang X.
        • Kwon J.H.
        • et al.
        Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids.
        Oncologist. 2013; 18: 212-220
        • Bar-Sela G.
        • Vorobeichik M.
        • Drawsheh S.
        • Omer A.
        • Goldberg V.
        • Muller E.
        The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care.
        Evid Based Complement Alternat Med. 2013; 2013
        • Bradford A.C.
        • Bradford W.D.
        Medical marijuana laws reduce prescription medication use in medicare part D.
        Health Aff. 2016; 35: 1230-1236
        • Boehnke K.F.
        • Litinas E.
        • Clauw D.J.
        Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain.
        J Pain. 2016; 17: 739-744
        • Reiman A.
        • Welty M.
        • Solomon P.
        Cannabis as a substitute for opioid-based pain medication: patient self-report.
        in: Cannabis and Cannabinoid Research. 2. 2017: 160-166
        • Harris D.
        • Jones R.T.
        • Shank R.
        • Nath R.
        • Fernandez E.
        • Goldstein K.
        • et al.
        Self-reported marijuana effects and characteristics of 100 San Francisco medical marijuana club members.
        J Addict Dis. 2000; 19: 89-103
        • Walsh Z.
        • Callaway R.
        • Belle-Isle L.
        • Capler R.
        • Kay R.
        • Lucas P.
        • et al.
        Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use.
        Int J Drug Policy. 2013; 24: 511-516
        • Swift W.
        • Gates P.
        • Dillon P.
        Survey of Australians using cannabis for medical purposes.
        Harm Reduction Journal. 2005; 2: 18
        • Ware M.
        • Adams H.
        • Guy G.
        The medicinal use of cannabis in the UK: results of a nationwide survey.
        Int J Clin Pract. 2005; 59: 291-295
        • Reiman A.
        Medical cannabis patients: patient profiles and health care utilization patterns.
        Complement Health Pract Rev. 2007; 12: 31-50
        • Portenoy R.K.
        • Ahmed E.
        Principles of opioid use in cancer pain.
        J Clin Oncol. 2014; 32: 1662-1670
        • Zenz M.
        • Strumpf M.
        • Tryba M.
        Long-term oral opioid therapy in patients with chronic nonmalignant pain.
        J Pain Symptom Manage. 1992; 7: 69-77
        • Taylor C.B.
        • Zlutnick S.I.
        • Corley M.J.
        • Flora J.
        The effects of detoxification, relaxation, and brief supportive therapy on chronic pain.
        Pain. 1980; 8: 319-329
        • Ricardo Buenaventura M.
        • Rajive Adlaka M.
        • Nalini Sehgal M.
        Opioid complications and side effects.
        Pain Physician. 2008; 11: S105-S120